Welcome to our dedicated page for Upstream Bio news (Ticker: UPB), a resource for investors and traders seeking the latest updates and insights on Upstream Bio stock.
Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody antagonist of the thymic stromal lymphopoietin (TSLP) receptor, for severe respiratory inflammatory diseases. The UPB news feed on Stock Titan highlights company announcements that explain how this single asset is progressing through clinical development and what that may mean for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD).
Investors following UPB can find press releases on positive top-line data from the VIBRANT Phase 2 trial in CRSwNP, where verekitug dosed every 12 weeks met its primary endpoint and key secondary endpoints with a generally well tolerated safety profile. News items also cover structural and mechanistic data presented at scientific congresses, detailing how verekitug binds the TSLP receptor, prevents TSLP binding, and outcompetes TSLP even in the presence of preformed receptor complexes.
Additional updates include reports on enrollment and design of the VALIANT Phase 2 trial in severe asthma, the VENTURE Phase 2 trial in COPD, and the VALOUR long-term extension study. Financial results releases, furnished via Form 8-K, summarize research and development spending related to verekitug and provide context on the company’s cash position and operating expenses.
News coverage also tracks Upstream Bio’s participation in healthcare and biopharma investor conferences, where management discusses clinical progress and upcoming milestones. For anyone monitoring UPB stock or the development of TSLP receptor-targeted therapies in respiratory disease, this page aggregates the company’s official news and regulatory communications in one place.
Upstream Bio (UPB) reported detailed Phase 2 VALIANT results for verekitug in adults with severe asthma, presented in an oral session at the ERS Congress 2026.
The trial met its primary endpoint, with verekitug 100 mg dosed every 12 weeks reducing the annualized asthma exacerbation rate (AAER) by 56% versus placebo (p<0.001), and statistically significant AAER reductions also seen in two other dose arms. Verekitug improved key secondary endpoints versus placebo at week 24, including lung function (FEV1), exhaled nitric oxide (FeNO), and asthma symptom control (ACQ-6), with benefits observed as early as week 2.
VALIANT enrolled 478 patients in a global, randomized, double-blind, placebo-controlled, dose-ranging design, regardless of baseline type‑2 biomarkers. Verekitug was generally well tolerated across all doses, with a safety profile consistent with prior studies and no meaningful impact of immunogenicity. Upstream Bio plans to start Phase 3 severe asthma and CRSwNP trials in Q1 2027 using a 400 mg every‑12‑week regimen.
Upstream Bio (Nasdaq: UPB) announced pivotal Phase 3 development plans for its TSLP receptor antagonist verekitug in both severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Following End-of-Phase 2 FDA meetings, the company plans one placebo-controlled Phase 3 trial per indication.
Both trials will evaluate a single high-dose subcutaneous regimen of 400 mg every 12 weeks, enrolling a combined total of about 1,500 patients in broad populations without baseline biomarker restrictions. Primary endpoints include annualized asthma exacerbation rates over 48 weeks and co-primary nasal polyp and congestion scores at 48 weeks for CRSwNP.
According to Upstream Bio, Phase 3 initiation remains on track for Q1 2027, and, with supportive data, the company expects to submit BLAs for both indications, targeting a potential U.S. launch as early as 2030.
Upstream Bio (Nasdaq: UPB) reported Q2 2026 results and clinical progress for its TSLP receptor antagonist verekitug in severe asthma, CRSwNP and COPD. The company remains on track to start Phase 3 trials in severe asthma and CRSwNP in Q1 2027, with End-of-Phase 2 FDA interactions ongoing.
Enrollment in the 481‑patient Phase 2 VENTURE COPD trial and the VALOUR long‑term severe asthma extension is complete, with key data expected in the second half of 2027. According to Upstream Bio, positive Phase 2 VIBRANT and VALIANT data support quarterly dosing. The company reported Q2 2026 collaboration revenue of $0.8 million, R&D expense of $36.1 million, G&A of $7.1 million and a net loss of $39.7 million. Cash, cash equivalents and short‑term investments totaled $261.3 million, expected to fund operations through 2027.
Upstream Bio (Nasdaq: UPB) reported new post-hoc responder analyses from the Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP).
Quarterly dosing led to clinically meaningful nasal polyp score improvements in ~80% of participants, with 72% improving in nasal congestion and 83% in total symptom score. A placebo-adjusted NPS reduction of -1.95 at Week 24 nearly doubled the 1.0-point threshold considered clinically meaningful. The company plans to initiate Phase 3 trials in CRSwNP and severe asthma in Q1 2027.
Upstream Bio (Nasdaq: UPB) will present additional efficacy data from the Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress in Istanbul on June 14, 2026.
The oral session will highlight a responder analysis of clinically meaningful improvements in key disease measures. Verekitug is described as the only known TSLP receptor antagonist currently in clinical development.
Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on treatments for inflammatory diseases and severe respiratory disorders, announced that CEO Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET.
A live webcast and replay will be available on the company’s investor relations website.
Upstream Bio (Nasdaq: UPB) reported new Phase 2 VIBRANT data on verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), including participants with comorbid asthma.
Verekitug 100 mg every 12 weeks improved ACQ-6 by placebo-adjusted LSM -0.9 at Week 24, cut rescue systemic steroids/CRSwNP surgery by 83%, improved nasal polyp and sinonasal symptom scores, and drove rapid, sustained reductions in type 2 inflammatory biomarkers. Phase 3 trials in CRSwNP and severe asthma are planned to begin dosing in Q1 2027.
Upstream Bio (Nasdaq: UPB) reported Q1 2026 results and clinical progress for verekitug in severe asthma, CRSwNP and COPD.
Cash, cash equivalents and short-term investments were $294.6 million as of March 31, 2026, expected to fund planned operations through 2027. R&D and G&A expenses rose year over year, driving a higher net loss.
The company plans End-of-Phase 2 FDA meetings for severe asthma and CRSwNP in mid-2026 and expects to initiate Phase 3 trials in Q1 2027. The Phase 2 COPD VENTURE trial has enrolled over 400 participants, with data now expected in the second half of 2027. A long-term severe asthma extension study completed enrollment with >90% retention, and new verekitug data are slated for ATS and EAACI 2026.
Upstream Bio (Nasdaq: UPB) will present new Phase 2 VIBRANT data for verekitug at the American Thoracic Society (ATS) 2026 International Conference in Orlando on May 18, 2026. Two posters (P1397, P1398) by Joseph K. Han, MD, report clinical effects in CRSwNP with comorbid asthma and impacts on nasal and blood biomarkers.
The presentations cover verekitug as a thymic stromal lymphopoietin (TSLP) receptor antagonist and include biomarker and clinical outcome data from the VIBRANT trial.
Upstream Bio (Nasdaq: UPB) outlined a Phase 3 plan for verekitug targeting severe asthma and CRSwNP with high-dose quarterly dosing and reported Q4 and full-year 2025 results on March 26, 2026. The company expects to begin Phase 3 dosing in Q1 2027.
Key facts: positive Phase 2 VALIANT asthma results (AAER reductions of 56% at 100 mg Q12W and 39% at 400 mg Q24W), VIBRANT CRSwNP NPS placebo-adjusted reductions of -1.95 (WOCF) and -1.77 (primary), PK modeling predicting 85%–96% target exposure at higher quarterly doses, and cash of $341.5 million expected to fund operations through 2027.